EGFR分子靶向治疗肝胆肿瘤的研究进展  

EGFR-targeted therapy for hepatobiliary cancers:recent progress

作　　者：邢荣春[1,2] 郑军[1,2] 

机构地区：[1]三峡大学第一临床医学院 [2]宜昌市中心人民医院普通外科,湖北宜昌443003

出　　处：《中国普通外科杂志》2013年第8期1069-1073,共5页China Journal of General Surgery

摘　　要：随着对肝胆肿瘤研究的不断深入,针对癌细胞异常通路和靶点的药物已经取得了很大的进展。目前针对表皮生长因子受体(EGFR)分子靶向药物已广泛应用于肝胆肿瘤的治疗,相对于传统化疗药物其已显现出其独特的优势,但其长期应用易出现耐药。笔者就EGFR分子靶向治疗在肝胆肿瘤的中的临床应用及其耐药机制方面进行综述,以期能对临床治疗提供新的思路。With the growth of research on hepatobiliary cancers,great progress has been achieved in the development of drugs targeting the abnormal pathways or molecules in cancer cells.At present,the drugs targeting the epidermal growth factor receptor（EGFR） has been widely used in hepatobiliary cancer therapy,and has exhibited unique advantages compared to traditional chemotherapy drugs,but may still give rise to drug resistance in long term use.This paper mainly addresses the clinical application of EGFR-targeted therapy in hepatobiliary cancers and the mechanisms of resistance,with the purpose of providing new insights for clinical practice.

关 键 词：肝肿瘤 治疗 胆道肿瘤 受体 表皮生长因子 综述文献 

分 类 号：R735.7[医药卫生—肿瘤]